New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis.

Bacillus Calmette-Guérin biomarker bladder cancer immunotherapy microbiome non-muscle-invasive bladder cancer omics prognostic factor

Journal

Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988

Informations de publication

Date de publication:
2020
Historique:
received: 14 02 2020
accepted: 09 06 2020
entrez: 28 8 2020
pubmed: 28 8 2020
medline: 28 8 2020
Statut: epublish

Résumé

About 70% of bladder cancers (BCs) are diagnosed as non-muscle-invasive BCs (NMIBCs), while the remaining are muscle-invasive BCs (MIBCs). The European Association of Urology (EAU) guidelines stratify NMIBCs into low, intermediate, and high risk for treatment options. Low-risk NMIBCs undergo only the transurethral resection of the bladder (TURB), whereas for intermediate-risk and high-risk NMIBCs, the transurethral resection of the bladder (TURB) with or without

Identifiants

pubmed: 32850635
doi: 10.3389/fchem.2020.00600
pmc: PMC7413024
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

600

Informations de copyright

Copyright © 2020 Pane, Mirabelli, Coppola, Illiano, Salvatore and Franzese.

Références

Eur Urol Oncol. 2019 May 14;:
pubmed: 31411976
Appl Microbiol Biotechnol. 2015 May;99(9):3741-54
pubmed: 25794874
Curr Opin Microbiol. 2017 Jun;37:95-102
pubmed: 28623720
J Med Chem. 2019 Jan 24;62(2):420-444
pubmed: 30035545
Sci Rep. 2018 Aug 14;8(1):12157
pubmed: 30108246
Front Oncol. 2018 Aug 23;8:315
pubmed: 30191140
Int J Mol Sci. 2020 Jan 31;21(3):
pubmed: 32023888
BJU Int. 2019 Jul;124(1):7-8
pubmed: 30663202
Cancer Chemother Pharmacol. 2018 Apr;81(4):629-645
pubmed: 29368051
Int J Urol. 2017 May;24(5):342-351
pubmed: 28326624
Expert Opin Biol Ther. 2016;16(2):273-83
pubmed: 26865049
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Front Cell Infect Microbiol. 2019 May 01;9:133
pubmed: 31119104
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Eur Urol Focus. 2018 Jul;4(4):503-505
pubmed: 30017900
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
World J Urol. 2018 Nov;36(11):1727-1740
pubmed: 29855698
Int J Mol Sci. 2019 Nov 29;20(23):
pubmed: 31795520
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Expert Opin Investig Drugs. 2019 Sep;28(9):757-770
pubmed: 31412742
Int J Mol Sci. 2017 Apr 12;18(4):
pubmed: 28417933
Eur J Cancer. 2019 Feb;108:111-119
pubmed: 30654296
Bioinformatics. 2016 Sep 1;32(17):2618-25
pubmed: 27197815
Cancers (Basel). 2020 Feb 24;12(2):
pubmed: 32102334
Curr Opin Urol. 2020 May;30(3):365-369
pubmed: 32141939
Sci Rep. 2020 Jan 14;10(1):281
pubmed: 31937798
Urol Clin North Am. 2020 Feb;47(1):111-118
pubmed: 31757294
Expert Opin Pharmacother. 2019 Aug;20(11):1387-1396
pubmed: 31081702
Ther Adv Urol. 2014 Oct;6(5):181-91
pubmed: 25276228
Microb Cell Fact. 2019 Mar 6;18(1):44
pubmed: 30841891
J Transl Med. 2019 May 22;17(1):172
pubmed: 31118074
Nat Rev Urol. 2019 Feb;16(2):73-74
pubmed: 30510275
J Clin Microbiol. 2010 Jun;48(6):2110-5
pubmed: 20392910
Biochem Biophys Res Commun. 2019 Jan 29;509(1):167-174
pubmed: 30579607
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
Am J Clin Exp Urol. 2014 Apr 15;2(1):57-61
pubmed: 25126590
Am J Hum Genet. 2015 May 7;96(5):797-807
pubmed: 25957468
Eur Urol Focus. 2020 May 15;6(3):479-489
pubmed: 30470647
J Glob Infect Dis. 2018 Oct-Dec;10(4):196-200
pubmed: 30581260
N Biotechnol. 2019 Jul 25;51:39-48
pubmed: 30790718
PLoS Comput Biol. 2019 Jun 17;15(6):e1006619
pubmed: 31206508
Diseases. 2018 Jun 29;6(3):
pubmed: 29966270
Front Chem. 2018 Mar 12;6:57
pubmed: 29594101
J Immunother Cancer. 2017 Nov 21;5(1):94
pubmed: 29157296
Open Heart. 2019 Apr 23;6(1):e000993
pubmed: 31168383
Curr Urol Rep. 2019 Nov 28;20(12):84
pubmed: 31781942
Eur Urol Focus. 2018 Jul;4(4):522-524
pubmed: 30197040
Cell Prolif. 2019 Nov;52(6):e12659
pubmed: 31469460
Nat Rev Urol. 2018 Dec;15(12):735-749
pubmed: 30315209
Gut. 2016 Feb;65(2):330-9
pubmed: 26338727
J Pathol. 2019 Oct;249(2):151-165
pubmed: 31102277
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019056
Front Oncol. 2019 Mar 01;9:121
pubmed: 30881921
Oncotarget. 2016 Jul 19;7(29):45479-45488
pubmed: 27323781
J Urol. 2013 Oct;190(4):1192-9
pubmed: 23648222
Eur Urol Focus. 2016 Apr;2(1):67-76
pubmed: 28723453
Expert Opin Pharmacother. 2019 Feb;20(2):201-208
pubmed: 30412003
J Transl Med. 2019 Oct 7;17(1):337
pubmed: 31590671
Adv Immunol. 2006;90:297-339
pubmed: 16730267
Biomed Res Int. 2018 Oct 3;2018:9836256
pubmed: 30402498
Front Immunol. 2019 Jun 26;10:1460
pubmed: 31297119
Urology. 2019 Apr;126:10-15
pubmed: 30615894
FEMS Microbiol Lett. 2010 May;306(2):103-9
pubmed: 20529131
Urol Clin North Am. 2020 Feb;47(1):35-46
pubmed: 31757298
World J Urol. 2019 Jan;37(1):15-29
pubmed: 30547196
Indian J Urol. 2018 Jan-Mar;34(1):11-19
pubmed: 29343907
Int J Biochem Cell Biol. 2015 Dec;69:121-31
pubmed: 26494003
Target Oncol. 2019 Jun;14(3):247-252
pubmed: 31073691

Auteurs

Katia Pane (K)

IRCCS SDN, Naples, Italy.

Peppino Mirabelli (P)

IRCCS SDN, Naples, Italy.

Luigi Coppola (L)

IRCCS SDN, Naples, Italy.

Ester Illiano (E)

Andrological and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, Italy.

Marco Salvatore (M)

IRCCS SDN, Naples, Italy.

Monica Franzese (M)

IRCCS SDN, Naples, Italy.

Classifications MeSH